Skip directly to site content
Are You Still There?
Due to inactivity, you will be signed out in two minutes unless you click 'Continue'.

Are you still there?

Due to inactivity, you will be signed out in two minutes unless
you click 'Continue'.

Panel:   4300 (Custom)
AR Bank # 0647 Escherichia coli
Study ID: DLX-07

Biosample Accession #: SAMN11953797

   




Panel:  Delafloxacin (DLX)


MIC (μg/ml) Results and Interpretation
Drug MIC (μg/ml) INT
Amikacin <=1.0S
Ampicillin 4S
Ampicillin/sulbactam 14S
Aztreonam <=2S
Cefazolin 2S
Cefepime <=0.5S
Cefotaxime <=0.5S
Cefotaxime/clavulanic acid 1 4<=0.25---
Cefoxitin 8S
Ceftazidime <=1.0S
Ceftazidime/avibactam 1<=0.5S
Ceftazidime/clavulanic acid 1 4<=0.5---
Ceftolozane/tazobactam 1<=0.5S
Ceftriaxone <=1.0S
Chloramphenicol 16I
Ciprofloxacin <=0.25S
Colistin 1I
Delafloxacin 20.06S
Doripenem <=0.12S
Ertapenem <=0.12S
Gentamicin 0.5S
Imipenem <=0.5S
Imipenem+chelators 3<=0.25---
Levofloxacin <=0.12S
Meropenem <=0.12S
Piperacillin/tazobactam 1<=4S
Tetracycline <=2S
Tigecycline 2<=0.5S
Tobramycin <=0.5S
Trimethoprim/sulfamethoxazole 1<=0.5S
Clinical and PK/PD data demonstrate colistin has limited clinical efficacy, even if an intermediate result is obtained. Alternative agents are strongly preferred. Colistin should be used in combination with one or more active antimicrobial agents. Consultation with an infectious disease specialist is recommended.
S – I –R Interpretation (INT) derived from CLSI 2025 M100 S35
1 Reflects MIC of first component
2 Based on FDA break points
3 Screen for metallo-beta-lactamase production [Rasheed et al. Emerging Infectious Diseases. 2013. 19(6):870-878]
4 Screen test for Extended-Spectrum-β-lactamase (ESBL) production (CLSI M100). Per CLSI, use of the ESBL test is limited to isolates of Klebsiella pneumoniae, K. oxytoca, Escherichia coli, and Proteus mirabilis. It should be noted that the presence of other β-lactamases (carbapenemases and/or AmpC) or porin alterations can mask the ESBL production and confound the interpretation of the ESBL screen test.
Device manufacturers and users of FDA cleared devices shall consult the FDA’s Antibacterial Susceptibility Test Interpretive Criteria       website for breakpoints recognized or recommended by FDA, and for information regarding FDA exceptions or additions to the applicable, recognized consensus standard.
Molecular Mechanisms of Resistance
CategoryGene
 
Disclaimer:
No disclaimer.
Propagation
MEDIUM
Medium: Trypticase Soy Agar with 5% Sheep Blood (BAP)

GROWTH CONDITIONS
Temperature: 35°C
Atmosphere: Aerobic

PROPAGATION PROCEDURE

Remove the sample vial to a container with dry ice or a freezer block. Keep vial on ice or block. (Do not let vial content thaw)

Open vial aseptically to avoid contamination

Using a sterile loop, remove a small amount of frozen isolate from the top of the vial

Aseptically transfer the loop to BAP

Use streak plate method to isolate single colonies

Incubate inverted plate at 35°C ± 2°C for 18-24 hrs.
Storage Temperature & Biosafety
STORAGE TEMPERATURE: -70°C

BIOSAFETY LEVEL: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the current publication of 'BioSafety in Microbiological and Biomedical Laboratories' from the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, and National Institutes of Health.



Disclaimer:

Isolate History
Date Action Performed
Top of Page
TOP